11 Best Short-Term Stocks to Invest in

4. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Performance 1 Year: -32.78%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) finds its way to our list of 11 best short-term stocks to invest in. The company’s weekly stock price performance surges following FDA approvals for EMPAVELI, second-quarter 2025 financial results, and capped royalty purchase agreements.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), headquartered in Massachusetts, is a global biopharmaceutical enterprise advancing treatments for diseases through complement system modulation. The company has pioneered first-in-class C3-targeting therapies for conditions such as geographic atrophy, rare kidney disorders, and PNH.

On July 28, 2025, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) received U.S. FDA approval for EMPAVELI for the treatment of patients 12 years and older with C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN). With this approval, EMPAVELI becomes the first and only FDA-approved treatment for primary IC-MPGN, adolescent patients with C3G, and post-transplant C3G disease recurrence, thus capturing the unmet demands for the drug.

On July 31, 2025, the company reported its Q2 2025 financial results, showing $178.5 million in total revenues. SYFOVRE U.S. net product revenue reached $150.6 million, with demand growing 6% quarter-over-quarter, maintaining its market leadership in GA.

In the report, the company also highlighted a capped royalty purchase agreement with Sobi, under which it would receive up to $300 million for 90% of ex-U.S. royalties of Aspaveli, including an upfront cash payment of $275 million. With this, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) focuses on pipeline development and commercial expansion without immediate financial pressure.

Following these developments, the stock price went up 27.70% this week, making a turnaround from its 32.78% yearly loss and drawing interest from traders eyeing biotech bounce-backs.